

Product DataSheet

Anti-Human IL-17A(Ixekizumab)

Catalog #: B21631113

This product is for research use only and is not intended for diagnostic use.

Product Overview Lot Specific Information

Volume: Lot Specific*

Product Concentration: Lot Specific*

Total Quality: Lot Specific*

Indicates that this detail will be noted on the certificate of analysis that ships along with this product.

Product Information

Target : IL-17A

Clone: Ixekizumab

Isotype: Human IgG4(S228P)-Kappa

Recommend Isotype Controls: Anti-HEL Human IgG4(S228P)-Kappa Isotype control

Expression System: CHO

Purity: > 95% as determined by SDS-PAGE

Endotoxin: <1EU/mg, determined by LAL gel clotting assay

Immunogen: N/A

Sterility: 0.2 µM filtered

Formulation: PBS, pH 7.4, contains no stabilizers or preservatives

Alternative Names: LY2439821;CTLA8; CTLA-8; CTLA8cytotoxic T-lymphocyte-associated serine esterase 8; Cytotoxic T-lymphocyte-associated antigen 8; IL17; IL-17; IL17A; IL-17A; IL-17Acytotoxic T-lymphocyte-associated protein 8; IL-17CTLA-8; IL17interleukin-17A; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8); interleukin 17A

Recommended Dilution Buffer: ABDB-1002 or PBS, pH 7.4,Contains no stabilizers or preservatives.

Storage: 2 weeks, 2-8°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage.

Protocol Information: Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further

optimized experimentally in a dose response or titration experiment.